NCT04831437RecruitingPhase 2
Clinical Response and Toxicity of Hypo-fractionated Chemoradiotherapy in Cervix Cancer
Comparison of Clinical Response and Toxicity of Hypo-fractionated Chemoradiation With Standard Treatment in Patients With Uterine Cervix Cancer
Source: ClinicalTrials.gov · Last updated 12 Oct 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Uterine cervix cancer can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment which can reduce costs and patient exposure. The aim of our study is to determine the non-inferiority of hypofractionated radiotherapy compared with conventional treatment.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 2 Apr 2021
- Start date
- 1 Apr 2021
- Primary completion date
- 31 Mar 2023
- Lead sponsor
- Tehran University of Medical Sciences
- Diseases
- Cervical cancer
- NCT number
- NCT04831437
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 60
- From 1 Apr 2021 to the primary completion date, 31 Mar 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Creatinine clearance less than 30ml/min, any histology other than the above, requirement of paraaortic lymph node irradiation, inflammatory bowel disease, connective tissue disorders, previous pelvic radiotherapy, FIGO stage IA or IV, Eastern Cooperative Oncology Group (ECOG) performance status greater than 2, History of previous hysterectomy
Who the study is looking for
- Pathology of squamous cell carcinoma (SCC), adenocarcinoma, adenosquamous carcinoma of uterine cervix- International Federation of Gynecology and Obstetrics (FIGO) stage IB, IIA, IIB, IIIA, IIIB (due to hydronephrosis without creatinine clearance compromise), IIIC1 (if less than 3 lymph nodes with size less than 3cm, and without involvement of common iliac chain)- Patient eligible for definitive chemoradiotherapy followed by brachytherapy
Age in the registry: 18 years to 85 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Imam khomeini hospital complex Coordinator of this site? Confirm its status | Tehran | Iran | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.